Third Quarter Financial Results On Form 6-K
Filed with ASX · · 125 pages · English
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes No Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes No TABLEOFCONTENTS Page Currency of Presentation and Certain Defined Terms 3 Forward-Looking Statements 3 Financial Statements 5 Manageme
Earlier from Mesoblast
- Successful Interim Analysis in Phase 3 Heart Failure Trial
- Mesoblast Receives A$3.7m From Aus Govt For R&D
- FDA Clears Heart Disease Trial At Boston Childrens Hospital
- Process Initiated For CHF P3 Interim Analysis
- Mesoblast Raises US$40 Million
Later from Mesoblast
- MSB Provides Q3 Operational Highlights and Financial Results
- Mesoblast RA Results Presented At EULAR Congress
- Positive Results of MSB Therapy in Osteoarthritis Published
- Potential For Accelerated Market Entry In Advanced CHF
- Fully Underwritten A$50.7 Million Entitlement Offer
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast